Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Tahir Masud1, Michael McClung2, Piet Geusens31Nottingham University Hospitals NHS Trust, Nottingham, UK; 2Oregon Osteoporosis Center, Portland, Oregon, USA; 3Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, BelgiumBackground: There is limit...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a9759c5606924662a6865b74c2f5497e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Tahir Masud1, Michael McClung2, Piet Geusens31Nottingham University Hospitals NHS Trust, Nottingham, UK; 2Oregon Osteoporosis Center, Portland, Oregon, USA; 3Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, BelgiumBackground: There is limited evidence to support the efficacy of current pharmaceutical agents in reducing the risk of hip fracture in older postmenopausal women with established osteoporosis.Objective: To clarify the efficacy of risedronate in reducing the risk of hip fracture in elderly postmenopausal women aged ≥70 years with established osteoporosis, i.e., those with bone mineral density-defined osteoporosis and a prevalent vertebral fracture.Methods: Post hoc analysis of the Hip Intervention Program (HIP) study, a randomized controlled trial comparing risedronate with placebo for reducing the risk of hip fracture in elderly women. Women aged 70 to 100 years with established osteoporosis (baseline femoral neck T-score ≤ −2.5 and ≥ 1 prior vertebral fracture) were included. The main outcome measure was 3-year hip fracture incidence in the risedronate and placebo groups.Results: A total of 1656 women met the inclusion criteria. After 3 years, hip fracture had occurred in 3.8% of risedronate-treated patients and 7.4% of placebo-treated patients (relative risk 0.54; 95% confidence interval 0.32–0.91; P = 0.019).Conclusion: Risedronate significantly reduced the risk of hip fracture in women aged up to 100 years with established osteoporosis.Keywords: osteoporosis, postmenopausal, hip fracture, risedronate |
|---|